Study to Assess Wellinks’ Digital Health Platform in Managing COPD

Patricia Inácio, PhD avatar

by Patricia Inácio, PhD |

Share this article:

Share article via email
reducing hospital readmission | COPD News Today | illustration of people looking at tablet

Adults with chronic obstructive pulmonary disease (COPD) are being recruited for a study into whether Wellinks’ first integrated virtual management system solution for COPD can improve patient outcomes.

The 24-week study is being conducted in partnership with the COPD Foundation, and it intends to enroll between 100 and 150 adult patients through the foundation’s COPD Patient-Powered Research Network (COPD PPRN).

Participants will test the Wellinks’ platform, designed to offer a combination of pulmonary rehabilitation and personalized coaching and monitoring through connected devices and a user-friendly app. Connected devices are the company’s Flyp nebulizer, spirometer, and pulse oximeter, Wellinks noted on a webpage.

Recommended Reading
NuvoAir Cough app

Cough Monitoring App for COPD Added to NuvoAir Home Platform

Those interested in this study need to join COPD PPRN, and can do so here.

Its goal is to assess whether the Wellinks platform aids in multiple patient outcomes, including health-related quality of life, healthcare resource utilization, and user satisfaction.

Researchers will also evaluate patients’ pulmonary function and symptoms, and a person’s engagement and use of the platform both over time and in relation to adjustments in the program.

“We are passionate about ensuring that people with COPD have access to the best treatment options available,” Ruth Tal-Singer, PhD, president and chief scientific officer of the COPD Foundation, said in a press release.

“We are excited to use our COPD PPRN to recruit individuals to assess this novel COPD management program. Especially after COVID-19, the Wellinks platform could be impactful in helping patients manage their health, and we look forward to learning more through this study,” Tal-Singer said.

The study follows a recent $25-million funding round that allowed Wellinks to expand access to its virtual management system for COPD, and support additional clinical studies into its virtual products.

“Clinical research is one of our top priorities at Wellinks — this collaborative study with the COPD Foundation is a critical milestone for demonstrating that our solutions have a positive clinical impact for patients,” said Pooja Doshi, director of product marketing at Wellinks.

“By working with the largest network of COPD patients ever established, this partnership will enable us to develop robust findings that will advance our solution and support our mission to help people live fully and breathe freely,” Doshi added.